NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Renwick MJ, Simpkin V, Mossialos E. Targeting innovation in antibiotic drug discovery and development: The need for a One Health – One Europe – One World Framework [Internet]. Copenhagen (Denmark): European Observatory on Health Systems and Policies; 2016. (Health Policy Series, No. 45.)
Targeting innovation in antibiotic drug discovery and development: The need for a One Health – One Europe – One World Framework [Internet].
Show details- 1.
- Mossialos E, et al. Policies and incentives for promoting innovation in antibiotic research. European Observatory on Health Systems and Policies. 2010. Available at www
.euro.who.int/__data /assets/pdf_file/0011/120143/E94241 .pdf. - 2.
- World Health Organization. Antimicrobial resistance: global report on surveillance. 2014. Available at http://apps
.who.int/iris /bitstream/10665 /112642/1/9789241564748_eng.pdf?ua=1. - 3.
- Liu Y-Y, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2015;16:161–168. [PubMed: 26603172]
- 4.
- The Review on Antimicrobial Resistance. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. 2014. Available at http://amr-review
.org /sites/default/files /AMR%20Review%20Paper %20-%20Tackling%20a %20crisis%20for%20the %20health%20and%20wealth %20of%20nations_1.pdf. - 5.
- The Review on Antimicrobial Resistance. Securing new drugs for future generations: the pipeline of antibiotics. 2015. Available at http://amr-review
.org /sites/default/files /SECURING%20NEW%20DRUGS %20FOR%20FUTURE%20GENERATIONS %20FINAL%20WEB_0.pdf. - 6.
- Transatlantic Taskforce on Antimicrobial Resistance. Recommendations for future collaboration between the US and EU. European Centre for Disease Prevention and Control. 2011. Available at http://ecdc
.europa.eu /en/activities/diseaseprogrammes /TATFAR /Documents/210911_TATFAR_Report.pdf. - 7.
- Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline in 2013. J Antibiot. 2013;66:571–591. [PubMed: 24002361]
- 8.
- Silver LL. Challenges of Antibacterial Discovery. Clinical Microbiology Reviews. 2011;24:71–109. [PMC free article: PMC3021209] [PubMed: 21233508]
- 9.
- Boucher HW, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1–12. [PubMed: 19035777]
- 10.
- Marks and Clerk. From rare to routine: life sciences report 2015 on medicines for rare diseases, vaccines and antibiotics. 2015. Available at www
.marks-clerk.com/MarksClerk /media/MCMediaLib /PDF’s /Reports/Life-Sciences-Report-2015-From-rare-to-routine.pdf. - 11.
- Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8:959–968. [PubMed: 19949401]
- 12.
- Chopra I, et al. Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement. Lancet Infect Dis. 2008;8:133–139. [PubMed: 18222164]
- 13.
- Spellberg B. The future of antibiotics. Crit Care. 2014;18:228–228. [PMC free article: PMC4075146] [PubMed: 25043962]
- 14.
- Outterson K, Powers JH, Daniel GW, McClellan MB. Repairing the broken market for antibiotic innovation. Health Aff (Millwood). 2015;34:277–285. [PubMed: 25646108]
- 15.
- Pew Charitable Trusts. Antibiotics currently in clinical development. 2015. Available at www
.pewtrusts.org/en /multimedia/data-visualizations /2014/antibiotics-currently-in-clinical-development. - 16.
- Theuretzbacher U. Recent FDA antibiotic approvals: good news and bad news. The Centre for Disease Dynamics, Economics & Policy; 2015. Available at http://cddep
.org/blog /posts/recent_fda_antibiotic _approvals_good _news_and_bad_news#sthash .WnWm2yyb.dpbs. - 17.
- BEAM Alliance. BEAM Alliance position paper: key action to reinvigorate investment and R&D in the antibacterial field now. 2015. Available at http:
//beam-alliance .eu/assets/2015-Position-Paper.pdf. - 18.
- Czaplewski L, et al. Alternatives to antibiotics – a pipeline portfolio review. Lancet Infect Dis. 2016;16:239–251. [PubMed: 26795692]
- 19.
- Chorzelski S, et al. Breaking through the wall: enhancing research and development of antibiotics in science and industry. Global Union for Antibiotic Research & Development Initiative; 2015. Available at www
.bmg.bund.de/fileadmin /dateien/Downloads/G/G7-Ges .Minister_2015 /Qualita_etswettbewerb _Gesundheitssystem _Whitepaper_2015-10-02 _Kurz_engl_….pdf. - 20.
- Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Disc. 2007;6:29–40. [PubMed: 17159923]
- 21.
- Joint Programming Initiative on Antimicrobial Resistance. Strategic Research Agenda. 2013. Available at www
.jpiamr.eu/download/SRA1_JPIAMR.pdf. - 22.
- Sharma P, Towse A. New drugs to tackle antimicrobial resistance. Office of Health Economics; 2011. Available at www
.ohe.org/publications /new-drugs-tackle-antimicrobial-resistance-analysis-eu-policy-options. - 23.
- EvaluatePharma. World preview 2014, outlook to 2020. 2014. Available at http://info
.evaluategroup .com/rs/evaluatepharmaltd /images/EP240614.pdf. - 24.
- Outterson K. New business models for sustainable antibiotics. Chatham House; 2014. Available at www
.chathamhouse.org /sites/files/chathamhouse /public/Research /Global%20Health/0214SustainableAntibiotics.pdf. - 25.
- Brogan DM, Mossialos E. Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model. Global Health. 2013;9:1–10. [PMC free article: PMC4226193] [PubMed: 24199835]
- 26.
- Kesselheim AS, Outterson K. Improving antibiotic markets for long term sustainability. Yale J Health Pol Law Ethics. 2013;11:101–168. [PubMed: 21381513]
- 27.
- Outterson K, Pogge T, Hollis A. Combatting antibiotic resistance through the Health Impact Fund. Oxford University Press; 2013. pp. 318–338.
- 28.
- Love J. Antibiotics innovation funding mechanism (AIFM). World Health Organization; 2013. Available at www
.who.int/phi/implementation/7.pdf. - 29.
- Morel CM, Mossialos E. Stoking the antibiotic pipeline. BMJ. 2010;340:c2115. [PubMed: 20483950]
- 30.
- Renwick MJ, Brogan DM, Mossialos E. A systematic review and critical assessment of incentive strategies for discovery and development of novel anti-biotics. J Antibiot. 2015;69:73–88. [PMC free article: PMC4775540] [PubMed: 26464014]
- 31.
- Kelly R, Zoubiane G, Walsh D, Ward R, Goossens H. Public funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic observational analysis. Lancet Infect Dis. 2016;16:431–440. [PMC free article: PMC4802226] [PubMed: 26708524]
- 32.
- Kelly R, Zoubiane G, Walsh D, Ward R. Joint Programming Initiative on Antimicrobial Resistance mapping report: scale and scope of anti-bacterial resistance research 2007–2013. Joint Programming Initiative on Antimicrobial Resistance; 2015. Available at www
.jpiamr.eu/wp-content /uploads/2016/04 /JPI-AMR-mapping-report-Final.pdf. - 33.
- Thomas D, Wessel C. Venture funding of therapeutic innovation. Biotechnology Industry Organization; 2015. Available at www
.bio.org/biovc-study. - 34.
- Joint Programming Initiative on Antimicrobial Resistance. at www
.jpiamr.eu. - 35.
- Transatlantic Task Force on Antimicrobial Resistance. at www
.cdc.gov/drugresistance/tatfar/ - 36.
- European and Developing Countries Clinical Trials Partnership. Annual Report 2014. Available at www
.edctp.org/web/app /uploads/2015/08/EDCTP _Annual_Report_2014_-_EN.pdf. - 37.
- World Health Organization. Global action plan on antimicrobial resistance: Draft resolution with amendments resulting from informal consultations. 2015. Available at http://apps
.who.int/gb /ebwha/pdf_files/WHA68 /A68_ACONF1Rev1-en.pdf?ua=1. - 38.
- World Health Organization/Drugs for Neglected Diseases Initiative. Investing in the development of new antibiotics and their conservation: a proposal for a Global Antibiotic Research and Development Facility to promote research, responsible use, and access to new antibiotics. 2015. Available at www
.who.int/phi/implementation /updt_global _antibiotic_r-d_facility.pdf. - 39.
- European Commission. European Commission launches €1m prize for a diagnostic test to combat antibiotic resistance. 2015. Available at http://ec
.europa.eu/research/index .cfm?pg =newsalert&year =2015&na=na-260215. - 40.
- Innovative Medicines Initiative. at www
.imi.europa.eu/ - 41.
- Rex JH. ND4BB: Addressing the antimicrobial resistance crisis. Nat Rev Microbiol. 2014;12:231–232.
- 42.
- New Drugs for Bad Bugs (ND4BB). at www
.imi.europa.eu/content/nd4bb. - 43.
- Baraldi E, et al. Solutions from other industries applicable to the antibiotic field. DRIVE-AB; 2016. Available at http://drive-ab
.eu/wp-content /uploads/2014 /09/WP2-Task-4-Report.pdf. - 44.
- Innovative Medicines Initiative 2. at www
.imi.europa.eu/content/imi-2. - 45.
- Innovative Medicines Initiative 2. The right prevention and treatment for the right patient at the right time. Strategic research agenda. 2014. Available at www
.imi.europa.eu/sites /default/files/uploads /documents/IMI2_SRA_March2014.pdf. - 46.
- European Investment Bank. InnovFin: EU finance for innovators – questions and answers. 2015. Available at www
.eib.org/attachments/innovfin_faq_en .pdf. - 47.
- European Investment Bank. InnovFin Infectious Disease. 2015. Available at www
.eib.org/attachments /documents/innovfin _infectious_diseases_flysheet_en.pdf. - 48.
- Brogan DM, Mossialos E. A critical analysis of the Review on Antimicrobial Resistance and the Infectious Disease Finance Facility. Global Health. 2016;12 [PMC free article: PMC4802890] [PubMed: 27000847]
- 49.
- Transatlantic Taskforce on Antimicrobial Resistance. Transatlantic Taskforce on Antimicrobial Resistance: progress report May 2014. 2014. Available at www
.cdc.gov/drugresistance /pdf/tatfar-progress_report_2014 .pdf. - 50.
- European Medicines Agency. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. 2013. Available at www
.ema.europa.eu/docs /en_GB/document_library /Scientific_guideline /2013/11/WC500153953.pdf. - 51.
- European Medicines Agency. Workshop on the therapeutic use of bacteriophages. 2015. Available at www
.ema.europa.eu/docs /en_GB/document_library /Other/2015/07/WC500189409.pdf. - 52.
- National Institute for Allergy and Infectious Diseases. National Institute for Allergy and Infectious Diseases (NIAID) 2015 fiscal budget. 2015. Available at https://www
.niaid.nih .gov/about/Documents/FY2015CJ.pdf. - 53.
- Antibacterial Resistance Leadership Group. at http://arlg
.org/ - 54.
- US National Institutes of Health. Request for information: antimicrobial resistance rapid, point-of-care diagnostic test challenge. 2015. Available at http://grants
.nih.gov /grants/guide/notice-files /NOT-OD-15-104.html. - 55.
- Larsen J. PCAST Briefing: BARDA’s Broad Spectrum Antimicrobials (BSA) Program. US White House; 2015. Available at www
.whitehouse.gov/sites /default/files/microsites /ostp/PCAST/Larsen,%20Joe.pdf. - 56.
- Office of the Assistant Secretary of Preparedness and Response. HHS forms strategic alliance to develop new antibiotics approach provides a pipeline of new drugs rather than a single medical countermeasure. US Department of Health and Human Services; 2013. Available at www
.phe.gov/Preparedness /news/Pages/strategic-alliance-130522.aspx. - 57.
- US Department of Health and Human Services. HHS enters into strategic alliance to accelerate new antibiotic development. 2015. Available at www
.hhs.gov/about/news /2015/09/16/hhs-enters-strategic-alliance-accelerate-new-antibiotic-development.html. - 58.
- The White House. National action plan for combating antibiotic-resistant bacteria. 2015. Available at www
.whitehouse.gov/sites /default/files/docs /national_action_plan _for_combating_antibotic-resistant _bacteria.pdf. - 59.
- Pew Charitable Trusts. GAIN: how a new law is stimulating the development of antibiotics. 2013. Available at www
.pewtrusts.org/en /research-and-analysis /issue-briefs/2013 /11/07/gain-how-a-new-law-is-stimulating-the-development-of-antibiotics/ - 60.
- Center for Drug Evaluation and Research. Development resources – Antibacterial Task Force: how CDER is establishing and promoting new approaches to antibacterial drug development. 2014. Available at www
.fda.gov/Drugs/DevelopmentApprovalProcess /DevelopmentResources/ucm406769.htm. - 61.
- Pew Charitable Trusts. LPAD: a regulatory pathway to develop antibiotics and fight drug-resistant infections. 2015. Available at www
.pewtrusts.org/en /research-and-analysis /q-and-a/2015/06/lpad-a-regulatory-pathway-to-develop-antibiotics-and-fight-drug-resistant-infections. - 62.
- Woodcock J. 21st Century Cures: examining ways to combat antibiotic resistance and foster new drug development. US Food and Drug Administration; 2014. Available at www
.fda.gov/newsevents /testimony/ucm415387.htm. - 63.
- Spellberg B, Sharma P, Rex JH. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. Nat Rev Drug Disc. 2012;11 [PMC free article: PMC3883457] [PubMed: 22293569]
- 64.
- Avorn J, Kesselheim AS. The 21st Century Cures Act — will it take us back in time? N Engl J Med. 2015;372:2473–2475. [PubMed: 26039522]
- 65.
- Page EL, et al. The Canadian Institutes of Health Research response to antimicrobial resistance. Canada Communicable Disease Report. 2015;41S
- 66.
- UK Medical Research Council. Annual report and accounts 2014/15. 2015. Available at www
.mrc.ac.uk/publications /browse/annual-report-and-accounts-2014-15/ - 67.
- Antimicrobial Resistance Funders’ Forum. at www
.mrc.ac.uk/research /initiatives/antimicrobial-resistance /antimicrobial-resistance-funders-forum/ - 68.
- UK Medical Research Council. Tackling AMR – A Cross Council Initiative. 2016. Available at www
.mrc.ac.uk/research /initiatives/antimicrobial-resistance /tackling-amr-a-cross-council-initiative/ - 69.
- UK Clinical Research Collaboration. Microbiology and infectious disease research funding. 2016. Available at www
.ukcrc.org/research-coordination /joint-funding-initiatives /microbiology-and-infectious-diseases-research-funding/ - 70.
- Nesta. Longitude Prize. at https:
//longitudeprize.org/ - 71.
- French National Research Agency. Annual report 2014. 2015. Available at www
.agence-nationale-recherche .fr/en/information /documents/annual-reports/ - 72.
- Institut National de la Sante de la Research Medicale. Inserm 2020 strategic plan. 2015. Available at http://english
.inserm .fr/about-inserm/the-institute-missions/strategic-documents. - 73.
- Institut National de la Sante de la Research Medicale. Scientific highlights 2014. 2015. Available at http://editions
.inserm .fr/Scientific%20highlights%202014. - 74.
- German Centre for Infection Research. Annual report 2014. 2015. Available at: www
.dzif.de/fileadmin /user_upload_dzif/Presse /Printmedien/DZIF-JB-2014-EN-WEB-barrierefrei.pdf. - 75.
- German Research Foundation. Annual report 2014. 2015. Available at www
.dfg.de/download/pdf /dfg_im_profil/geschaeftsstelle /publikationen/dfg_jb2014 .pdf. - 76.
- Netherlands Organisation for Health Research and Development. Priority Medicines Antimicrobial Resistance: research programme. 2009. Available at www
.zonmw.nl/fileadmin /documenten/Priority_medicines_AMR /ZonMW _Programmatekst_AMR__def_.pdf. - 77.
- Netherlands Organisation for Health Research and Development. Priority Medicines Antimicrobial Resistance. at www
.zonmw.nl/en/programmes /priority-medicines-antimicrobial-resistance /priority-medicines-antimicrobial-resistance/ - 78.
- Swedish Research Council. at www
.vr.se/inenglish.4 .12fff4451215cbd83e4800015152.html. - 79.
- Swedish Research Council Formas. at www
.formas.se/en/About-Sustainability-Formas-Research-Council /This-is-how-our-work-is-directed/ - 80.
- Vinnova. at www
.vinnova.se/en/ - 81.
- Gavi Alliance. Advanced market commitments for pneumococcal vaccines: annual report. 2015. Available at www
.gavi.org/funding/pneumococcal-amc/ - 82.
- Office of Budget. Overview of FY2016 president’s budget. National Institutes of Health; 2015. Available at https:
//officeofbudget .od.nih.gov/pdfs/FY16 /Overview%20(Volume%20I).pdf. - 83.
- The 10 x ‘20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis. 2010;50:1081–1083. [PubMed: 20214473]
- 84.
- Adam T, Rottingen J-A, Kieny M-P. Informing the establishment of the WHO Global Observatory on Health Research and Development: a call for papers. Health Res Policy Syst. 2015;13:1–4. [PMC free article: PMC4328039] [PubMed: 25645000]
- 85.
- Hoffman SJ, et al. Strategies to achieving global collective action on antimicrobial resistance. Bull World Health Organ. 2015;93:867–876. [PMC free article: PMC4669731] [PubMed: 26668439]
- 86.
- Van Boeckel TP, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14:742–750. [PubMed: 25022435]
- 87.
- Laxminarayan R, et al. Access to effective antimicrobials: a worldwide challenge. Lancet. 2016;387:168–175. [PubMed: 26603918]
- 88.
- Daulaire N, Bang A, Tomson G, Kalyango JN, Cars O. Universal access to effective antibiotics is essential for tackling antibiotic resistance. J Law Med Ethics. 2015;43 Suppl 3:17–21. [PubMed: 26243238]
- 89.
- Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–171. [PMC free article: PMC4340604] [PubMed: 25530442]
- 90.
- Liu L, et al. Global, regional, and national causes of child mortality in 2000– 13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015;385:430–440. [PubMed: 25280870]
- 91.
- World Health Organization. Consultation of member states and relevant partners on options for establishing a global development and stewardship framework to combat antimicrobial resistance. 2016. Available at www
.who.int/phi/news /AMRbackground_document_consultation.pdf. - 92.
- Hoffman SJ, Outterson K. What will it take to address the global threat of antibiotic resistance? J Law Med Ethics. 2015;43:363–368. [PubMed: 26242959]
- 93.
- Hoffman S. J, et al. An international legal framework to address antimicrobial resistance. Bull World Health Organ. 2015;93:66. [PMC free article: PMC4339972] [PubMed: 25883395]
- 94.
- Clift C, et al. Towards a new global business model for antibiotics: delinking revenues from sales. Chatham House; 2015. Available at www
.chathamhouse.org /sites/files/chathamhouse /field/field_document /20151009NewBusinessModelAntibioticsCliftGopinathanMorelOuttersonRottingenSo.pdf. - 95.
- Review on Antimicrobial Resistance. Declaration by the pharmaceutical, biotechnology and diagnostics industries on combating antimicrobial resistance. 2016. Available at http://amr-review
.org /sites/default/files /Declaration_of_Support _for_Combating_AMR_Jan_2016.pdf. - 96.
- Rex JH, Outterson K. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. Lancet Infect Dis. 2016;16:500–505. [PubMed: 27036356]
- 97.
- World Health Organization. Prequalification of medicines by WHO. 2013. Available at www
.who.int/mediacentre /factsheets/fs278/en/
- References - Targeting innovation in antibiotic drug discovery and developmentReferences - Targeting innovation in antibiotic drug discovery and development
Your browsing activity is empty.
Activity recording is turned off.
See more...